CATALOGO DEI PRODOTTI DELLA RICERCA

QUAGLIA, Francesca Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.192
NA - Nord America 3.033
AS - Asia 2.302
SA - Sud America 261
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 138
OC - Oceania 20
Totale 9.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.854
RU - Federazione Russa 1.667
SG - Singapore 878
IT - Italia 770
BD - Bangladesh 327
VN - Vietnam 312
CN - Cina 310
BR - Brasile 175
GB - Regno Unito 175
HK - Hong Kong 172
DE - Germania 108
BJ - Benin 87
IN - India 85
CA - Canada 81
FR - Francia 81
NL - Olanda 57
SE - Svezia 56
MX - Messico 52
ES - Italia 47
IE - Irlanda 46
NG - Nigeria 37
PL - Polonia 37
FI - Finlandia 34
JP - Giappone 34
ID - Indonesia 30
AR - Argentina 29
AT - Austria 22
KR - Corea 22
TR - Turchia 22
ZA - Sudafrica 21
TN - Tunisia 19
AU - Australia 17
EC - Ecuador 17
IQ - Iraq 12
RO - Romania 12
PH - Filippine 11
PT - Portogallo 11
SA - Arabia Saudita 11
PK - Pakistan 10
UA - Ucraina 10
VE - Venezuela 10
CH - Svizzera 9
CO - Colombia 9
EG - Egitto 9
HN - Honduras 9
BE - Belgio 8
BG - Bulgaria 8
IL - Israele 8
JM - Giamaica 8
CL - Cile 7
LT - Lituania 7
AE - Emirati Arabi Uniti 6
GR - Grecia 6
GT - Guatemala 6
PS - Palestinian Territory 6
QA - Qatar 6
TH - Thailandia 6
CR - Costa Rica 5
IR - Iran 5
MY - Malesia 5
PY - Paraguay 5
TT - Trinidad e Tobago 5
ET - Etiopia 4
NI - Nicaragua 4
PE - Perù 4
TG - Togo 4
TW - Taiwan 4
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
LB - Libano 3
MA - Marocco 3
OM - Oman 3
UZ - Uzbekistan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
CG - Congo 2
DZ - Algeria 2
GE - Georgia 2
HR - Croazia 2
KE - Kenya 2
KZ - Kazakistan 2
MD - Moldavia 2
MT - Malta 2
NP - Nepal 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TZ - Tanzania 2
XK - ???statistics.table.value.countryCode.XK??? 2
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CU - Cuba 1
CY - Cipro 1
DK - Danimarca 1
FJ - Figi 1
GY - Guiana 1
Totale 8.993
Salva come PNG Salva come JPEG
Città #
Moscow 716
San Jose 590
Singapore 522
Ashburn 423
Verona 231
Council Bluffs 223
Dallas 182
Hong Kong 166
New York 139
Los Angeles 98
Ho Chi Minh City 97
Chandler 96
Cotonou 87
Beijing 74
Hanoi 72
Milan 64
Buffalo 56
Orem 48
Dublin 44
London 39
Rome 39
Santa Clara 37
The Dalles 37
Phoenix 36
Bologna 35
São Paulo 32
Warsaw 32
Mexico City 28
Chennai 27
Montreal 27
Tokyo 26
Xi'an 23
Atlanta 22
Brooklyn 22
Denver 22
Houston 22
Munich 21
Stockholm 21
Toronto 21
Abuja 19
Haiphong 18
Helsinki 18
Lagos 18
Naples 18
Seattle 18
Da Nang 17
Poplar 17
Jacksonville 16
Johannesburg 15
Frankfurt am Main 14
Jakarta 14
Querétaro 14
Southend 14
Manchester 13
Mumbai 13
Amsterdam 12
Chicago 11
Falkenstein 11
Melbourne 11
Padua 11
Princeton 11
Wilmington 11
Boston 10
Bucharest 10
Charlotte 10
Lawrence 10
Lisbon 10
Madrid 10
Stuttgart 10
Venice 10
Boardman 9
Florence 9
Philadelphia 9
Tianjin 9
Turin 9
Vienna 9
Ankara 8
Bari 8
Belfast 8
City of London 8
Dong Ket 8
Hyderabad 8
Jinan 8
Lappeenranta 8
Redondo Beach 8
Columbus 7
Hürth 7
New Delhi 7
Ninh Bình 7
Tunis 7
Brussels 6
Cagliari 6
Catania 6
Doha 6
Guangzhou 6
Guayaquil 6
Istanbul 6
Nuremberg 6
Paris 6
Seoul 6
Totale 5.132
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 307
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 233
The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia 212
Fentanyl buccal tablet: a new breakthrough pain medication in early management of severe vaso-occlusive crisis in sickle cell disease. 205
Chronic lymphocytic leukemia and mantle cell lymphoma: similarities and differences from an integrated biological and clinical approach 203
Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia 182
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 182
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 177
Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi 172
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 166
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 164
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group 161
Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease 157
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 149
Differential diagnosis of lymphocytosis in routine laboratory practice: the contribution of Sysmex- XN9100 147
Bendamustine plus rituximab: is it a BRIGHT idea? 143
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 140
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy 126
GENOMIC ANALYSES OF PATIENTS WITH MANTLE CELL LYMPHOMA THAT WERE REFRACTORY OR RELAPSED AFTER INDUCTION THERAPY: RESULTS FROM THE FIL_MANTLE- FIRST BIO STUDY 122
SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE 121
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 117
Different infiltration patterns within the tumor microenvironment can identify mantle cell lymphoma patients with different clinical outcomes. Results from a pilot clinical-pathological study 112
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 112
Mantle cell lymphoma patients in first relapse: we pretty much know what to do 108
Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin's Lymphoma: A Case Report and Review of the Literature 101
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 97
THE ROLE OF STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 96
BCR signaling activity stratifies patents with MCL with divergent clinical outcome 93
IN CHRONIC LYMPHOCYTIC LEUKAEMIA WITH COMPLEX KARYOTYPE, MAJOR STRUCTURAL ABNORMALITIES IDENTI- FY A SUBSET OF PATIENTS WITH INFERIOR OUTCOME AND DISTINCT BIOLOGIC CHARACTERISTICS 91
R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy 90
B-CELL RECEPTOR SIGNALING ACTIVITY IDENTIFIES PATIENTS WITH MANTLE CELL LYMPHOMA AT HIGHER RISK OF PROGRESSION 90
A phospho-specific flow cytometry study reveals the impact of BCR signaling activation in mantle cell lymphoma progression and therapy 89
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF THE B-CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA 87
THE PROGNOSTIC ROLE OF DEL 9P21.3 (CDKN2A) IN PATIENTS WITH MANTLE CELL LYMPHOMA. RESULTS FROM THE FIL_MANTLE-FIRST BIO STUDY 86
ARGO, AUTOMATIC RECORD GENERATOR IN ONCOLOGY: MULTICENTRIC VALIDATION OF A NEW TOOL FOR AUTO- MATIC CONVERSION OF “REAL-LIFE” HEMOLYMPHOPATHOL- OGY REPORTS IN STANDARDIZED ECRF 84
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation 82
ACTIVATION OF BCR SIGNALING REWIRES THE RESPONSE OF BCR-ASSOCIATED KINASES TO IBRUTINIB IN MANTLE CELL LYMPHOMA CELLS 82
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH R/R CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 82
An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920) 80
GENETIC AND EPIGENETIC MECHANISMS REGULATING CATALASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA 80
FITNESS STATUS AND TIME TO FIRST PROGRESSION IN ELDERLY PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE “ELDERLY MANTLE-FIRST” STUDY 78
Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study 76
Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs 75
DIFFERENT MICROENVIRONMENTAL PATTERNS OF T-CELL INFILTRATION CAN IDENTIFY MANTLE CELL LYMPHOMA PATIENTS WITH DISTINCT CLINICAL OUTCOMES. RESULTS FROM A PILOT CLINICAL-PATHOLOGICAL STUDY 75
THE ROLE OF STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE 73
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study 71
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations 71
OUTCOME OF 100 TP53-DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED FRONT-LINE WITH IBRUTINIB. A REAL-LIFE CAMPUS CLL STUDY. 70
A REAL-LIFE STUDY OF DARATUMUMAB-BORTEZOMIB-DEX- AMETHASONE (DVD) IN LENALIDOMIDE EXPOSED/REFRAC- TORY MULTIPLE MYELOMA PATIENTS: A REPORT FROM THE MYELOMA TRIVENETO WORKING GROUP 70
B-CELL RECEPTOR SIGNALING PROFILES IN MANTLE CELL LYMPHOMA: A BARCODING AND PHOSPHO-SPECIFIC FLOW CYTOMETRY APPROACH 69
B-CELL RECEPTOR SIGNALING PROFILES IDENTIFY SUBSETS OF MANTLE CELL LYMPHOMA PATIENTS WITH DIFFERENT CLINICAL OUTCOMES 68
Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. 65
A MULTI‐CENTER REAL‐LIFE ANALYSIS ON PATIENTS WITH LARGE B‐CELL LYMPHOMA AFTER FAILURE OF CAR‐T CELLS THERAPY 64
Association of genetic polymorphisms with differential catalase gene expression in prognostic groups of chronic lymphocytic leukemia patients. 63
Minimal Residual Disease Evaluation in the Context of V-Rbac, a Risk-Tailored Phase II Trial of the Fondazione Italiana Linfomi (FIL) 62
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness 61
RESPONSE TO IBRUTINIB OF AN AGGRESSIVE IG-A LYMPHOPLASMACYTIC LYMPHOMA CARRYING THE MYD88 L265P GENE MUTATION 61
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 61
THE PROGNOSTIC SIGNIFICANCE OF MYC AND BCL2 PROTEIN DOUBLE EXPRESSION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, NOS, IN THE ABSENCE OF MYC REARRANGEMENT 61
OBINUTUZUMAB PLUS CHLORAMBUCIL VERSUS IBRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYM- PHOCYTIC LEUKEMIA WITHOUT TP53 DISRUPTIONS. A CAMPUS CLL STUDY 60
IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL‐LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY 60
A MULTI-CENTER REAL-LIFE ANALYSIS ON PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FAILURE OF CAR-T CELLS THERAPY 60
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report 58
VENETOCLAX IN MULTI-RELAPSED MANTLE CELL LYMPHOMA PATIENTS: A REAL-LIFE MULTICENTRIC EXPERIENCE 58
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.” 55
CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS 55
Worldwide Examination of Patients with CLL Hospitalized for COVID-19 55
Callosal agenesis in craniofrontonasal dysplasia 54
Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus 54
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study 53
Paraaortic PEComa 53
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 53
HBV REACTIVATION IN CLL PATIENTS WITH OCCULT HBV INFECTION TREATED WITH IBRUTINIB WITH OR WITHOUT VIRAL PROPHYLAXIS. A RETROSPECTIVE MULTICENTRIC GIMEMA STUDY 53
Atherosclerotic ectasia of coronary arteries 52
Simultaneous abdominal histoplasmosis and cerebral toxoplasmosis in an AIDS patient 50
AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS 50
Fluorescent cell barcoding and phospho-specific flow cytometry characterize B-cell receptor signaling profiles associated with different clinical outcome in mantle cell lymphoma 50
Recurrent infiltrative cancer of the cheek: a case report 49
VALIDATION OF AN INFECTION RISK SYSTEM IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH THE IDELALISIB-RITUXIMAB REGIMEN 49
Left main coronary artery aneurysm 48
Diagnosis of groove pancreatitis in patient with chronic pancreatitis and recurrent abdominal pain 47
Brachial aneurysm following arterovenous fistula ligation 47
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 46
Regulation of catalase gene expression in chronic lymphocytic leukemia patients. 46
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: results from the ELDERLY MANTLE-FIRST study 46
Gastroepiploic artery bypass graft 46
Notch signaling is a poor prognostic factor in Acute Myeloid Leukemia (AML). 46
Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia 46
Subacute combined degeneration 46
The presentation of a possible effect induced by human contact with a source of high voltage electrical current 45
Cavernous sinus thrombosis: exophtalmos in a patient with Internal Carotid Artery (ICA) aneurysm 45
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 45
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 44
Preoperative visualisation of Adamkiewicz artery by computed tomography in a patient with aortic aneurysm 44
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 44
Ultrasound guided radiofrequency thermoablation of thyroid substernal goiter 42
In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics 42
Squamous cell carcinoma of the penis: a case report 41
Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion 39
COMPARISON OF EEG-FMRI DATA TO INVASIVE ELECTROPHYSIOLOGICAL REGISTRATION IN CRYPTOGENIC FOCAL EPILEPSY 39
Totale 8.637
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.492
article - articoli 14.412
book - libri 0
conference - conferenze 7.628
curatela - curatele 0
other - altro 2.452
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.984
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202277 0 19 0 5 11 5 0 4 3 3 6 21
2022/2023265 10 31 23 43 23 70 0 25 23 1 9 7
2023/2024192 7 6 10 18 26 29 12 17 11 17 28 11
2024/2025636 21 30 48 93 29 23 39 63 74 38 64 114
2025/20267.313 83 137 129 779 2.707 590 604 495 512 325 446 506
2026/2027559 269 290 0 0 0 0 0 0 0 0 0 0
Totale 9.143